TENX (Tenax Therapeutics) Volatility: 61.43% (As of Jun. 25, 2026)


TENX Tenax Therapeutics Inc TENX
22 GF Score
Price $12.86
! 2 Warning Signs
View Full Analysis

What is Tenax Therapeutics Volatility?

Tenax Therapeutics TENX -0.69% 22 Volatility is 61.43% as of Jun. 25, 2026. GuruFocus rates TENX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-06-25), Tenax Therapeutics's Volatility is 61.43%.

Tenax Therapeutics  (NAS:TENX) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Tenax Therapeutics Volatility Related Terms

TENX vs RZLT, PRLD, NAGE: Volatility Comparison

For the Biotechnology subindustry, Tenax Therapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tenax Therapeutics Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's Volatility distribution charts can be found below:

* The bar in red indicates where Tenax Therapeutics's Volatility falls into.


TENX
22GF Score
Tenax Therapeutics Inc TENX
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tenax Therapeutics  (NAS:TENX) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 61.43% mean?
Tenax Therapeutics (TENX) has a Volatility of 61.43% as of Jun. 25, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Tenax Therapeutics and its competitors.
Is Tenax Therapeutics' Volatility too high?
Tenax Therapeutics' current Volatility is 61.43%. Overall, Tenax Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Tenax Therapeutics' Volatility compare to RZLT and PRLD?
Tenax Therapeutics' Volatility of 61.43% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Tenax Therapeutics and its competitors. Tenax Therapeutics's current Volatility is 61.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenax Therapeutics stock overvalued right now?
Tenax Therapeutics (TENX) has a current Volatility of 61.43%. The current Volatility is 61.43%. Tenax Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Tenax Therapeutics (TENX), the current Volatility is 61.43% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tenax Therapeutics Business Description

Other Exchanges YBO0:Germany
Address 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
22GF Score

Get the complete analysis for TENX

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.86
Price